Tg Therapeutics (TGTX) Enterprise Value (2011 - 2026)

Tg Therapeutics' Enterprise Value history runs 16 years deep, the most recent figure standing at -$75.1 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 72.82% year-over-year to -$75.1 million; the TTM figure through Mar 2026 stood at -$75.1 million (up 72.82% YoY), while the FY2025 annual figure was -$64.1 million, up 51.21% from the prior year.
• Enterprise Value for Q1 2026 stood at -$75.1 million, down from -$64.1 million in the prior quarter.
• The five-year high for Enterprise Value was -$64.1 million in Q4 2025, with the low at -$341.0 million in Q3 2024.
• The 5-year median for Enterprise Value is -$209.8 million (2024), against an average of -$194.1 million.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value plunged 50.16% in 2024, then jumped 72.82% in 2026.
• Tg Therapeutics' Enterprise Value stood at -$161.7 million in 2022, then plunged by 34.53% to -$217.5 million in 2023, then jumped by 39.55% to -$131.5 million in 2024, then soared by 51.21% to -$64.1 million in 2025, then slipped by 17.05% to -$75.1 million in 2026.
• Business Quant data shows TGTX's Enterprise Value at -$75.1 million in Q1 2026, -$64.1 million in Q4 2025, and -$235.8 million in Q3 2025.